glp-1 weight loss dosage Medications for Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness GLP-1 drugs: Lower dose or

Additionally, a person with a BMI of 30 kg/m2 or greater can find treatment through Semaglutide GLP-1 without weight-related conditions

Abbreviations ADA: Adenosine deaminase ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Afib: Atrial fibrillation BNP: Brain natriuretic peptide cAMP: Cyclic adenosine 3,5-monophosphate CI: Confidence interval CKD: Chronic kidney disease CVD: Cardiovascular disease CVOTs: Cardiovascular outcome trials DPP-4: Dipeptidyl peptidase-4 DPP-4i: DPP-4 inhibitor eGFR: Estimated glomerular filtration rate FDA: Food and Drug Administration GAS: Interferon-gamma-activated sequence GIP: Glucose-dependent insulinotropic polypeptide GLP-1: Glucagon-like peptide-1 GLP-1R: GLP-1 receptor GLP-1RAs: Glucagon-like peptide-1 receptor agonists HbA1c: Glycated hemoglobin HDL: High-density lipoprotein HF: Heart failure HNF-1: Hepatocyte nuclear factor-1 HR: Hazard ratio hs-CRP: High-sensitivity C-reactive protein IL-12: Interleukin-12 IVUS: Intravascular ultrasound LDL: Low-density lipoprotein LVEF: Left ventricular ejection fraction MACE: Major adverse cardiovascular events MI: Myocardial infarction MMPs: Matrix metalloproteases PAI-1: Plasminogen activator inhibitor-1 PCI: Percutaneous coronary intervention PKA: Protein kinase A PWV: Pulse wave velocity SGLT-2i: Sodium/glucose cotransporter-2 inhibitors STAT1: Signal transducer and activator of transcription 1 T1DM: Type 1 diabetes mellitus T2DM: Type 2 diabetes mellitus TGF-: Transforming growth factor- TLR4: Toll-like receptor 4 TNF-: Tumor necrosis factor- TRIF: TIR-domain-containing adapter-inducing interferon- UKPDS: United Kingdom Prospective Diabetes Study VLDL: Very low-density lipoprotein References Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al

PMID: 33184945

In one of the AWARD studies Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5), it showed that Trulicity was more effective in causing weight loss compared to another type 2 diabetes medication, called sitagliptin (a DPP-4 inhibitor)

This connection between the gut & pancreatic islets may be responsible for ~50% of postprandial insulin release (Perley & Kipnis, J Clin Invest 46:1954-1962